Building successful biotechnology companies requires strong international partnerships alongside scientific innovation. Events that bring together biotechnology companies, pharmaceutical organizations, investors, and innovation stakeholders provide valuable opportunities to establish collaborations that accelerate the development and commercialization of new healthcare technologies.
Fetalix participated for the first time in BIO-Europe Spring 2026, one of Europe's leading partnering conferences for the life sciences industry. The event brought together companies, investors, and innovation leaders from across the global biotechnology ecosystem to explore strategic partnerships and advance the translation of scientific discoveries into healthcare solutions.
Throughout the conference, Fetalix engaged with representatives from the pharmaceutical and biotechnology sectors, exploring opportunities for collaboration in the regenerative medicine and biomaterials space. The event also provided an opportunity to strengthen relationships within the Portuguese biotechnology ecosystem and exchange perspectives with entrepreneurs, investors, and innovation support organizations committed to advancing biomedical innovation.
Participation in BIO-Europe Spring 2026 represents an important step in expanding Fetalix's international network and reinforcing its commitment to building strategic partnerships that support the translation of its regenerative medicine technologies from research to clinical application.
March 25, 2026
